Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.

Abstract

We describe the clinical outcome of asfotase alfa therapy in a 16-year-old boy with severe childhood hypophosphatasia (HPP), who began therapy at age 15 years. The patient was diagnosed with HPP at age 2 years when he presented with genu varum and premature loss of primary teeth. He had a history of multiple fractures requiring 16 orthopedic surgeries with rod and pin placement in his lower extremities. He had chronic skeletal pain and used cane to ambulate with great difficulty. His height Z score at age 15 years was - 5. He had severe scoliosis and deformity of both legs. Bone radiograph showed hypomineralization and characteristic "tongues" of radiolucency in the distal radius and ulna. His serum alkaline phosphatase level was stable, with elevated serum pyridoxal 5'-phosphate and urine phosphoethanolamine, consistent with HPP. He was started on asfotase alfa 2 mg/kg given subcutaneously thrice weekly. He had marked clinical improvement in mobility with no report of pain after 3 months of treatment. At 6 month, he walked without cane and participated in outdoor activities with peers. Bone radiograph at 6 months showed striking improvement in previous radiolucent areas. At 9 months, his annualized growth velocity was 9.5 cm/year, while growth velocity of arm span was 12 cm/year. However, at 12 months, he was noted to have worsening scoliosis from 60 degrees before therapy to 110 degrees, with a slight decrease in height, necessitating a spinal fusion surgery. In conclusion, treatment with asfotase alfa significantly improved physical function, pain, overall quality of life, and skeletal radiographic findings in this patient. Close monitoring for progression of scoliosis in adolescents with HPP treated with asfotase alfa is recommended.

• Authors: S A Bowden, B H Adler
• Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (Osteoporos Int) Vol. 29 Issue 2 Pg. 511-515 (02 2018) ISSN: 1433-2965 [Electronic] England
• PMID: 29046930 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulin G
• Recombinant Fusion Proteins
• Alkaline Phosphatase
• asfotase alfa

Topics

• Adolescent
• Alkaline Phosphatase (therapeutic use)
• Bone Demineralization, Pathologic (diagnostic imaging, drug therapy, etiology)
• Enzyme Replacement Therapy (methods)
• Humans
• Hypophosphatasia (complications, drug therapy, physiopathology)
• Immunoglobulin G (therapeutic use)
• Male
• Quality of Life
• Radiography
• Recombinant Fusion Proteins (therapeutic use)
• Scoliosis (etiology)